BetterLife Announces Intent to Complete Private Placement of Units
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 03 2024
0mins
Source: newsfilter
- Private Placement Offering: BetterLife Pharma Inc. plans a Non-Brokered Private Placement offering of up to $500,000 to advance its lead compound BETR-001 and for general working capital purposes.
- About BetterLife Pharma: The company focuses on developing non-hallucinogenic LSD-based therapeutics for mental disorders, with compounds like BETR-001 and BETR-002 targeting neuro-psychiatric and neurological disorders.
- BETR-001: A non-hallucinogenic LSD derivative in preclinical studies, unique for being unregulated and self-administered, with patents covering treatment of major depressive disorder, anxiety disorder, neuropathic pain, and other related disorders.
- BETR-002: Based on honokiol from magnolia bark, this compound is in preclinical studies and aims to treat anxiety-related disorders, including benzodiazepine dependency, with pending method of use and formulations patent.
- Cautionary Note: The news release includes forward-looking statements about product development, licensing, commercialization, and regulatory compliance, highlighting risks and uncertainties that could impact actual results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
